Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region

ABSTRACT Genetic studies have implicated the cytosolic juxtamembrane region of the Kit receptor tyrosine kinase as an autoinhibitory regulatory domain. Mutations in the juxtamembrane domain are associated with cancers, such as gastrointestinal stromal tumors and mastocytosis, and result in constitutive activation of Kit. Here we elucidate the biochemical mechanism of this regulation. A synthetic peptide encompassing the juxtamembrane region demonstrates cooperative thermal denaturation, suggesting that it folds as an autonomous domain. The juxtamembrane peptide directly interacted with the N-terminal ATP-binding lobe of the kinase domain. A mutation in the juxtamembrane region corresponding to an oncogenic form of Kit or a tyrosine-phosphorylated form of the juxtamembrane peptide disrupted the stability of this domain and its interaction with the N-terminal kinase lobe. Kinetic analysis of the Kit kinase harboring oncogenic mutations in the juxtamembrane region displayed faster activation times than the wild-type kinase. Addition of exogenous wild-type juxtamembrane peptide to active forms of Kit inhibited its kinase activity in trans, whereas the mutant peptide and a phosphorylated form of the wild-type peptide were less effective inhibitors. Lastly, expression of the Kit juxtamembrane peptide in cells which harbor an oncogenic form of Kit inhibited cell growth in a Kit-specific manner. Together, these results show the Kit kinase is autoinhibited through an intramolecular interaction with the juxtamembrane domain, and tyrosine phosphorylation and oncogenic mutations relieved the regulatory function of the juxtamembrane domain.

[1]  C. Deberry,et al.  Lyn Associates with the Juxtamembrane Region of c-Kit and Is Activated by Stem Cell Factor in Hematopoietic Cell Lines and Normal Progenitor Cells* , 1997, The Journal of Biological Chemistry.

[2]  John Kuriyan,et al.  Crystal structure of the Src family tyrosine kinase Hck , 1997, Nature.

[3]  Joseph Schlessinger,et al.  Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism , 1996, Cell.

[4]  F. Ruddle,et al.  Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus. , 1988, The EMBO journal.

[5]  S. Hubbard,et al.  Crystal structure of the tyrosine kinase domain of the human insulin receptor , 1994, Nature.

[6]  D. Linnekin,et al.  Early signaling pathways activated by c-Kit in hematopoietic cells. , 1999, The international journal of biochemistry & cell biology.

[7]  L. Rohrschneider,et al.  Tyrosine 569 in the c-Fms juxtamembrane domain is essential for kinase activity and macrophage colony-stimulating factor-dependent internalization , 1994, Molecular and cellular biology.

[8]  L. Ashman,et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.

[9]  W. Berdel,et al.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.

[10]  T. Pawson,et al.  Structural Basis for Autoinhibition of the EphB2 Receptor Tyrosine Kinase by the Unphosphorylated Juxtamembrane Region , 2001, Cell.

[11]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[12]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[13]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[14]  W. Miller,et al.  Investigating the substrate specificity of the HER2/Neu tyrosine kinase using peptide libraries. , 2000, Cancer letters.

[15]  P. Cohen,et al.  A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. , 2001, Molecular Cell.

[16]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[17]  T. Pawson,et al.  Phosphorylation of Tyrosine Residues in the Kinase Domain and Juxtamembrane Region Regulates the Biological and Catalytic Activities of Eph Receptors , 2000, Molecular and Cellular Biology.

[18]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[19]  J. Lasota,et al.  Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.

[20]  S. Jiang,et al.  Direct Association of Csk Homologous Kinase (CHK) with the Diphosphorylated Site Tyr568/570 of the Activated c-KIT in Megakaryocytes* , 1997, The Journal of Biological Chemistry.

[21]  Y. Ma,et al.  Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. , 2001, Leukemia research.

[22]  R. Zahler.  Enzyme Structure and Mechanism , 1979, The Yale Journal of Biology and Medicine.

[23]  S. Lev,et al.  Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Kassel,et al.  Characterization of pp60c-src tyrosine kinase activities using a continuous assay: autoactivation of the enzyme is an intermolecular autophosphorylation process. , 1995, Biochemistry.

[25]  T. Naoe,et al.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000, Oncogene.

[26]  Morgan Huse,et al.  Crystal Structure of the Cytoplasmic Domain of the Type I TGF β Receptor in Complex with FKBP12 , 1999, Cell.

[27]  Helmut E. Meyer,et al.  Conformational Switch and Role of Phosphorylation in PAK Activation , 2001, Molecular and Cellular Biology.

[28]  D. DiMaio,et al.  A single amino acid substitution in a WW‐like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation , 1998, The EMBO journal.

[29]  S. Hubbard.  Autoinhibitory mechanisms in receptor tyrosine kinases. , 2002, Frontiers in bioscience : a journal and virtual library.

[30]  G. Laurent,et al.  Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase Cγ , 2001, Oncogene.

[31]  al. et,et al.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B , 1995, Science.

[32]  Duc Hung Le,et al.  SHP-1 Binds and Negatively Modulates the c-Kit Receptor by Interaction with Tyrosine 569 in the c-Kit Juxtamembrane Domain , 1998, Molecular and Cellular Biology.

[33]  W. Miller,et al.  Engineering the Substrate Specificity of the Abl Tyrosine Kinase* , 1999, The Journal of Biological Chemistry.

[34]  Y. Ma,et al.  Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. , 1999, The Journal of investigative dermatology.

[35]  H. Serve,et al.  Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. , 1994, The Journal of biological chemistry.

[36]  A. Kazlauskas,et al.  Full Activation of the Platelet-derived Growth Factor β-Receptor Kinase Involves Multiple Events* , 1998, The Journal of Biological Chemistry.

[37]  N. Ferrara,et al.  A repressor sequence in the juxtamembrane domain of Flt‐1 (VEGFR‐1) constitutively inhibits vascular endothelial growth factor‐dependent phosphatidylinositol 3′‐kinase activation and endothelial cell migration , 2000, The EMBO journal.

[38]  J. Casnellie.  Assay of protein kinases using peptides with basic residues for phosphocellulose binding. , 1991, Methods in enzymology.

[39]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[40]  Michael J. Eck,et al.  Three-dimensional structure of the tyrosine kinase c-Src , 1997, Nature.

[41]  Wange Lu,et al.  Structure of PAK1 in an Autoinhibited Conformation Reveals a Multistage Activation Switch , 2000, Cell.

[42]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[43]  Irwin A. Rose,et al.  Enzyme structure and mechanism (2nd edn): by Alan Fersht, W. H. Freeman & Co., 1985. £14.95 pbk, £28.95 hbk (xxi + 475 pages) ISBN 0 7167 1615 1 , 1985 .

[44]  Laurence H. Pearl,et al.  Crystal Structure of Glycogen Synthase Kinase 3β Structural Basis for Phosphate-Primed Substrate Specificity and Autoinhibition , 2001, Cell.